{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:08:55Z","timestamp":1789434535478,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Anhui province","award":["No.2208085MH217"],"award-info":[{"award-number":["No.2208085MH217"]}]},{"name":"the Research Fund of Anhui Institute of Translational Medicine","award":["No. 2022zhyx-C51"],"award-info":[{"award-number":["No. 2022zhyx-C51"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01692-1","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:24:24Z","timestamp":1746797064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma"],"prefix":"10.1007","volume":"25","author":[{"given":"Haotian","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"1692_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"1692_CR2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"1692_CR3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17:543\u201356.","journal-title":"Nat Rev Cancer"},{"key":"1692_CR4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/cancers13061285","volume":"13","author":"A Schavgoulidze","year":"2021","unstructured":"Schavgoulidze A, Cazaubiel T, Perrot A, et al. Multiple myeloma: heterogeneous in every way. Cancers. 2021;13:1285.","journal-title":"Cancers"},{"key":"1692_CR5","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Terpos E, Dimopoulos MA. How I treat relapsed multiple myeloma. Blood. 2022;139:2904\u201317.","journal-title":"Blood"},{"key":"1692_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2021.07.011","volume":"79","author":"L Cristinziano","year":"2022","unstructured":"Cristinziano L, Modestino L, Antonelli A, et al. Neutrophil extracellular traps in cancer. Semin Cancer Biol. 2022;79:91\u2013104.","journal-title":"Semin Cancer Biol"},{"key":"1692_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","volume":"14","author":"S Xiong","year":"2021","unstructured":"Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14:173.","journal-title":"J Hematol Oncol"},{"key":"1692_CR8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22:173\u201387.","journal-title":"Nat Rev Immunol"},{"key":"1692_CR9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2015.10.040","volume":"371","author":"IR Ramachandran","year":"2016","unstructured":"Ramachandran IR, Condamine T, Lin C, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett. 2016;371:117\u201324.","journal-title":"Cancer Lett"},{"key":"1692_CR10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","volume":"16","author":"KH Lee","year":"2017","unstructured":"Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2017;16:1160\u201373.","journal-title":"Autoimmun Rev"},{"key":"1692_CR11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1078-0432.CCR-13-1950","volume":"20","author":"R Ria","year":"2014","unstructured":"Ria R, Catacchio I, Berardi S, et al. HIF-1\u03b1 of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res. 2014;20:847\u201358.","journal-title":"Clin Cancer Res"},{"key":"1692_CR12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","volume":"120","author":"A Seckinger","year":"2012","unstructured":"Seckinger A, Meissner T, Moreaux J, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120:1087\u201394.","journal-title":"Blood"},{"key":"1692_CR13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12967-023-04494-9","volume":"21","author":"H Shi","year":"2023","unstructured":"Shi H, Pan Y, Xiang G, et al. A novel NET-related gene signature for predicting DLBCL prognosis. J Transl Med. 2023;21:630.","journal-title":"J Transl Med"},{"key":"1692_CR14","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"1692_CR15","doi-asserted-by":"crossref","first-page":"1096852","DOI":"10.3389\/fonc.2022.1096852","volume":"12","author":"C Marcon","year":"2022","unstructured":"Marcon C, Simeon V, Deias P, et al. Expert\u2019s consensus on the definition and management of high risk multiple myeloma. Front Oncol. 2022;12:1096852.","journal-title":"Front Oncol"},{"key":"1692_CR16","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962\u201372.","journal-title":"Blood"},{"key":"1692_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","volume":"11","author":"I Spaan","year":"2018","unstructured":"Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol. 2018;11:67.","journal-title":"J Hematol Oncol"},{"key":"1692_CR18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/tox.24082","volume":"39","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang C, Yu Y. Comprehensive analyses and experimental verification of NETs and an EMT gene signature for prognostic prediction, immunotherapy, and chemotherapy in pancreatic adenocarcinoma. Environ Toxicol. 2024;39:2006\u201323.","journal-title":"Environ Toxicol"},{"key":"1692_CR19","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2174\/0113862073282003240119064337","volume":"27","author":"G Mo","year":"2024","unstructured":"Mo G, Long X, Cao L, et al. A six-gene prognostic model based on neutrophil extracellular traps (NETs)-related gene signature for lung adenocarcinoma. Comb Chem High Throughput Screen. 2024;27:1969\u201383.","journal-title":"Comb Chem High Throughput Screen"},{"key":"1692_CR20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/2326-6066.CIR-22-0896","volume":"11","author":"D Xiao","year":"2023","unstructured":"Xiao D, Zeng T, Zhu W, et al. ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers. Cancer Immunol Res. 2023;11:1367\u201383.","journal-title":"Cancer Immunol Res"},{"key":"1692_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053260","volume":"8","author":"MF Calmon","year":"2013","unstructured":"Calmon MF, Mota MT, Babeto \u00c9, et al. Overexpression of ANXA1 in penile carcinomas positive for high-risk HPVs. PLoS ONE. 2013;8: e53260.","journal-title":"PLoS ONE"},{"key":"1692_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0002-9440(10)63098-2","volume":"164","author":"JM Garcia Pedrero","year":"2004","unstructured":"Garcia Pedrero JM, Fernandez MP, Morgan RO, et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol. 2004;164:73\u20139.","journal-title":"Am J Pathol"},{"key":"1692_CR23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96\u2013100.","journal-title":"Nature"},{"key":"1692_CR24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41419-022-05172-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, He Z, Liu X, et al. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell Death Dis. 2022;13:718.","journal-title":"Cell Death Dis"},{"key":"1692_CR25","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1038\/s41388-021-01786-6","volume":"40","author":"L Mao","year":"2021","unstructured":"Mao L, Yuan W, Cai K, et al. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis. Oncogene. 2021;40:3610\u201323.","journal-title":"Oncogene"},{"key":"1692_CR26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15:77.","journal-title":"J Hematol Oncol"},{"key":"1692_CR27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2016.03.012","volume":"60","author":"YL Chang","year":"2016","unstructured":"Chang YL, Yang CY, Lin MW, et al. High co-expression of PD-L1 and HIF-1\u03b1 correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer. 2016;60:125\u201335.","journal-title":"Eur J Cancer"},{"key":"1692_CR28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12957-021-02482-1","volume":"20","author":"Y Yang","year":"2022","unstructured":"Yang Y, Ding R, Wang R. Identification of candidate targets and mechanisms involved in miRNA regulation in multiple myeloma. World J Surg Oncol. 2022;20:23.","journal-title":"World J Surg Oncol"},{"key":"1692_CR29","first-page":"65","volume":"3","author":"AS Bie","year":"2016","unstructured":"Bie AS, Fernandez-Guerra P, Birkler RI, et al. Effects of a mutation in the HSPE1 gene encoding the mitochondrial co-chaperonin HSP10 and its potential association with a neurological and developmental disorder. Front Mol Biosci. 2016;3:65.","journal-title":"Front Mol Biosci"},{"key":"1692_CR30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/15548627.2022.2148808","volume":"19","author":"Y Lei","year":"2023","unstructured":"Lei Y, Klionsky DJ. MCOLN3\/TRPML3 bridges the regulation of autophagosome biogenesis by PtdIns3P and the calcium channel. Autophagy. 2023;19:377\u20138.","journal-title":"Autophagy"},{"key":"1692_CR31","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.febslet.2009.12.056","volume":"584","author":"X Cheng","year":"2010","unstructured":"Cheng X, Shen D, Samie M, Xu H. Mucolipins: Intracellular TRPML1-3 channels. FEBS Lett. 2010;584:2013\u201321.","journal-title":"FEBS Lett"},{"key":"1692_CR32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-0854.2009.00924.x","volume":"10","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Soyombo AA, Tjon-Kon-Sang S, et al. The Ca(2+) channel TRPML3 regulates membrane trafficking and autophagy. Traffic. 2009;10:1157\u201367.","journal-title":"Traffic"},{"key":"1692_CR33","volume":"239","author":"J Li","year":"2022","unstructured":"Li J, Chen C, Chen B, Guo T. High FN1 expression correlates with gastric cancer progression. Pathol Res Pract. 2022;239: 154179.","journal-title":"Pathol Res Pract"},{"key":"1692_CR34","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang H, Zhang J, Li H, et al. FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers. Front Oncol. 2022;12: 918719.","journal-title":"Front Oncol"},{"key":"1692_CR35","volume":"13","author":"XX Zhang","year":"2022","unstructured":"Zhang XX, Luo JH, Wu LQ. FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. Front Genet. 2022;13: 913659.","journal-title":"Front Genet"},{"key":"1692_CR36","volume":"120","author":"Z Gu","year":"2023","unstructured":"Gu Z, Wang L, Dong Q, et al. Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78. Proc Natl Acad Sci USA. 2023;120: e2215744120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1692_CR37","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2020.12.030","volume":"160","author":"JC Devlin","year":"2021","unstructured":"Devlin JC, Axelrad J, Hine AM, et al. Single-cell transcriptional survey of Ileal-anal pouch immune cells from ulcerative colitis patients. Gastroenterology. 2021;160:1679\u201393.","journal-title":"Gastroenterology"},{"key":"1692_CR38","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/ATVBAHA.120.315061","volume":"40","author":"J Wenzel","year":"2020","unstructured":"Wenzel J, Spyropoulos D, Assmann JC, et al. Endogenous THBD (Thrombomodulin) mediates angiogenesis in the ischemic brain-brief report. Arterioscler Thromb Vasc Biol. 2020;40:2837\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1692_CR39","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1172\/JCI2006","volume":"101","author":"H Weiler-Guettler","year":"1998","unstructured":"Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101:1983\u201391.","journal-title":"J Clin Invest"},{"key":"1692_CR40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3835(00)00617-0","volume":"161","author":"Y Hosaka","year":"2000","unstructured":"Hosaka Y, Higuchi T, Tsumagari M, Ishii H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett. 2000;161:231\u201340.","journal-title":"Cancer Lett"},{"key":"1692_CR41","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/hep.1840210511","volume":"21","author":"T Suehiro","year":"1995","unstructured":"Suehiro T, Shimada M, Matsumata T, et al. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 1995;21:1285\u201390.","journal-title":"Hepatology"},{"key":"1692_CR42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bmt.1705000","volume":"36","author":"B Sirohi","year":"2005","unstructured":"Sirohi B, Powles R, Mehta J, et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant. 2005;36:19\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"1692_CR43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/cancers14010113","volume":"14","author":"O Alkharabsheh","year":"2021","unstructured":"Alkharabsheh O, Trisel Z, Badami S, et al. Checkpoint inhibitors in multiple myeloma: intriguing potential and unfulfilled promises. Cancers. 2021;14:113.","journal-title":"Cancers"},{"key":"1692_CR44","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3390\/cancers11122009","volume":"11","author":"H Tamura","year":"2019","unstructured":"Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Immunotherapy for multiple myeloma. Cancers. 2019;11:2009.","journal-title":"Cancers"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01692-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:02Z","timestamp":1764917342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01692-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01692-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.\n                      Ethics approval and consent to participate.\n                      This study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University, and informed consent was obtained from all patients. All experiments were conducted by relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}